These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21120332)

  • 1. [High cost drugs for rare diseases in Brazil: the case of lysosomal storage disorders].
    de Souza MV; Krug BC; Picon PD; Schwartz IV
    Cien Saude Colet; 2010 Nov; 15 Suppl 3():3443-54. PubMed ID: 21120332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
    Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
    Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Care in the treatment of orphan diseases at home].
    Bénévise N
    Soins; 2003; (672):49-51. PubMed ID: 12655827
    [No Abstract]   [Full Text] [Related]  

  • 4. Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I.
    Boy R; Schwartz IV; Krug BC; Santana-da-Silva LC; Steiner CE; Acosta AX; Ribeiro EM; Galera MF; Leivas PG; Braz M
    J Med Ethics; 2011 Apr; 37(4):233-9. PubMed ID: 21266385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Principle of protection and treatment of rare genetic diseases in Brazil: the case of lysosomal storage disorders].
    Boy R; Schramm FR
    Cad Saude Publica; 2009 Jun; 25(6):1276-84. PubMed ID: 19503958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why Genzyme can charge so much for Cerezyme.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A15. PubMed ID: 16502533
    [No Abstract]   [Full Text] [Related]  

  • 7. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.
    Moran M
    PLoS Med; 2005 Sep; 2(9):e302. PubMed ID: 16138789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One drug to treat many diseases: unlocking the economic trap of rare diseases.
    Pierzynowska K; Kamińska T; Węgrzyn G
    Metab Brain Dis; 2020 Dec; 35(8):1237-1240. PubMed ID: 32926291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [How does the landscape change in lysosomal storage disease].
    Parini R
    Pediatr Med Chir; 2007; 29(5):275-8. PubMed ID: 18402399
    [No Abstract]   [Full Text] [Related]  

  • 10. Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy.
    Roberts EA; Herder M; Hollis A
    CMAJ; 2015 Apr; 187(6):422-425. PubMed ID: 25712953
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease.
    Hollak CE; Weinreb NJ
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):205-18. PubMed ID: 25987174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new era of hope for the world's most neglected diseases.
    The
    PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Jumpstarting research into neglected diseases.
    Leslie M
    Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [What opportunities are afforded by enzyme replacement therapy].
    Huppertz HI
    Z Rheumatol; 2006 Feb; 65(1):44-5. PubMed ID: 16804994
    [No Abstract]   [Full Text] [Related]  

  • 16. Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease.
    Moore DF; Ries M; Forget EL; Schiffmann R
    Pharmacoeconomics; 2007; 25(3):201-8. PubMed ID: 17335306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming the Next Barriers to Successful Therapy.
    Cohen IJ; Baris H; Mistry PK; Sands MS
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():629. PubMed ID: 27491209
    [No Abstract]   [Full Text] [Related]  

  • 18. Drugs for exceptionally rare diseases: do they deserve special status for funding?
    Hughes DA; Tunnage B; Yeo ST
    QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Orphan drugs and sick patients].
    Kristiansen IS; Olsen JA
    Tidsskr Nor Laegeforen; 2005 Apr; 125(8):992. PubMed ID: 15852066
    [No Abstract]   [Full Text] [Related]  

  • 20. Reducing the cost of rare disease drugs.
    Lancet; 2015 Feb; 385(9970):746. PubMed ID: 25752156
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.